RepositraK (Park City Group, Inc.) — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2023, filed November 14, 2023. This is the company’s fiscal first quarter of fiscal 2024; the request metadata’s “2023 Q1” does not match the filing period. The filing compares the quarter with the three months ended September 30, 2022.
Business context
The company operates a SaaS platform for food-sector retailers, wholesalers, distributors and suppliers. Its offerings cover compliance management, food traceability, e-commerce and supply-chain management, delivered through a hub-and-spoke model in which retailers and wholesalers may require suppliers to use its services.
Financial performance
| Metric | Quarter ended Sep. 30, 2023 | Prior-year quarter | Change |
|---|---|---|---|
| Revenue | $5.06 million | $4.72 million | +7% |
| Operating income | $1.20 million | $1.23 million | Down $28,000 |
| Net income | $1.38 million | $1.29 million | +7% |
| Net income attributable to common shareholders | $1.23 million | $1.14 million | +8% |
| Basic and diluted EPS | $0.07 | $0.06 | Up $0.01 |
| Net cash from operating activities | $1.52 million | $1.81 million | Down 16% |
Recurring subscription and support revenue was $5.05 million, versus $4.68 million; setup and training revenue was $13,427, versus $42,500. Cost of services and product support was 15% of revenue, compared with 18%. Operating margin was approximately 23.7%, versus 26.0%; net margin was approximately 27.2% in both periods. Higher interest income contributed to net income growth: interest income was $258,161, versus $79,092.
Financial position and liquidity
At September 30, 2023, cash was $23.70 million, total current assets $27.20 million, current liabilities $4.28 million, and working capital $22.92 million. The current ratio was 6.36. Total liabilities were $4.61 million; bank debt was zero. Notes payable and financing leases totaled about $296,000, and operating lease liabilities totaled about $308,000.
Operating cash flow was positive, but receivables increased and accounts payable declined. Investing cash flow was zero. Financing activities used $1.81 million, including $1.32 million for common-stock repurchases and $421,248 in dividends. Cash declined $294,000 during the quarter.
Material changes, outlook and risks
- Management attributed revenue growth to increased demand for recurring services amid greater food-safety and traceability concerns. It is emphasizing subscription revenue over non-recurring transactions.
- Sales and marketing expense rose 25% to $1.51 million, mainly due to trade shows, FSMA 204 marketing and travel. General and administrative expense rose 5%; depreciation and amortization rose 31%, partly reflecting assets acquired in the prior fiscal year.
- The company spent approximately $420,000 on security, backup, storage and redundancy upgrades, financed through leasing. Management cited an effective APR of 4.45% in its discussion; elsewhere the filing reports a 4.55% fixed effective APR for leases.
- The board approved redemption and retirement of all Series B and Series B-1 preferred shares at $10.70 per share, for an aggregate $8.96 million, over three years. No shares had been redeemed by September 30. Preferred dividends accrued in the quarter were $146,611.
- The board declared a quarterly common-stock cash dividend of $0.015 per share ($0.06 annualized). Management expects cash and operating funds to cover operations, debt obligations, dividends and the planned preferred redemption for at least 12 months, while cautioning that future capital needs depend on growth and spending.
- Management said global pandemics, bank failures and geopolitical conflicts had not materially adversely affected the business through the quarter, but their future effects are uncertain. It also identified interest-rate exposure on cash and short-term investments; bank-line balance was zero.
- Management discussed potential demand from FDA food-traceability requirements under FSMA Section 204(d). Actual adoption, compliance timing and resulting revenue are uncertain. The filing reports no material pending or threatened legal proceedings, no new risk factors beyond those in the June 30, 2023 Form 10-K, and effective disclosure controls.
Important facts for investors to verify
- Confirm the period: the filing is for the quarter ended September 30, 2023, not calendar-year 2023 Q1.
- Track recurring-revenue growth and whether FSMA 204-related demand converts into customer adoption and revenue.
- Monitor cash use from common dividends, repurchases and the planned $8.96 million preferred-stock redemption; no preferred shares had yet been redeemed at quarter-end.
- Reconcile the filing’s lease APR references of 4.45% and 4.55%, and verify the timing and financing of lease obligations.
- Verify share counts: the balance sheet reports 18,171,068 common shares outstanding at September 30, while the cover reports 18,158,205 issued and outstanding as of November 14.
- Assess the impact of receivables and working-capital movements on operating cash flow, which declined year over year despite higher net income.